June 2, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer

Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more

June 1, 2018 Bio/Pharma/CRO

European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

Basel, 01 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence An important new treatment option has been approved for patients in Europe with HER2-positive early breast cancer at high risk of recurrence in a setting where the goal of treatment is cure High... Read more

June 1, 2018 Uncategorized

European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

Basel, 01 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence An important new treatment option has been approved for patients in Europe with HER2-positive early breast cancer at high risk of recurrence in a setting where the goal of treatment is cure High... Read more

June 1, 2018 Acad, Gov/Utilities Clinical Research/Diagn. PR/Corporate

Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 01 June 2018 Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting The data to be presented further demonstrate potential of TECENTRIQ and Avastin combination in renal cell carcinoma, a type of kidney cancer, and hepatocellular... Read more

May 29, 2018 Bio/Pharma/CRO

Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone

Basel, 29 May 2018 Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival... Read more

May 25, 2018 PR/Corporate

Reminder: Invitation to Roche Analyst Event at ASCO 2018

Basel, 25 May 2018 Reminder: Invitation to Roche Analyst Event at ASCO 2018 Monday, 4 June 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June... Read more

May 21, 2018 Bio/Pharma/CRO

Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors

Basel, 21 May 2018 Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, Hemlibra reduced bleeds by 68 percent... Read more

May 17, 2018 Bio/Pharma/CRO PR/Corporate

Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death

Basel, 17 May 2018 Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death Investigator-assessed longer follow-up of the ALEX study demonstrated sustained benefit in the reduction of the risk of disease progression or death (57%)... Read more

May 17, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel

Basel, 17 May 2018 Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups... Read more